PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Positive Phase 3 SHIELD II Trial Results – D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveil ed a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the O besity and Diabetes Market Successful